Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Retrospective analysis of unknown primary cancers with malignant pleural effusion at initial diagnosis.

Ebata T, Okuma Y, Nakahara Y, Yomota M, Takagi Y, Hosomi Y, Asami E, Omuro Y, Hishima T, Okamura T, Takiguchi Y.

Thorac Cancer. 2016 Jan;7(1):39-43. doi: 10.1111/1759-7714.12271. Epub 2015 May 7.

2.

Hsp70 (HSPA1) Lysine Methylation Status as a Potential Prognostic Factor in Metastatic High-Grade Serous Carcinoma.

Jakobsson ME, Moen A, Davidson B, Falnes PØ.

PLoS One. 2015 Oct 8;10(10):e0140168. doi: 10.1371/journal.pone.0140168. eCollection 2015.

3.

Diagnostic accuracy of calretinin for malignant mesothelioma in serous effusions: a meta-analysis.

Li D, Wang B, Long H, Wen F.

Sci Rep. 2015 Mar 30;5:9507. doi: 10.1038/srep09507.

4.

Diagnostic accuracy of Ber-EP4 for metastatic adenocarcinoma in serous effusions: a meta-analysis.

Wang B, Li D, Ou X, Yi Q, Feng Y.

PLoS One. 2014 Sep 17;9(9):e107741. doi: 10.1371/journal.pone.0107741. eCollection 2014.

5.

Use of circulating tumor cell technology (CELLSEARCH) for the diagnosis of malignant pleural effusions.

Schwed Lustgarten DE, Thompson J, Yu G, Vachani A, Vaidya B, Rao C, Connelly M, Udine M, Tan KS, Heitjan DF, Albelda S.

Ann Am Thorac Soc. 2013 Dec;10(6):582-9. doi: 10.1513/AnnalsATS.201303-068OC.

6.

Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.

Nasreen N, Khodayari N, Mohammed KA.

Am J Cancer Res. 2012;2(2):222-34. Epub 2012 Feb 15.

7.

Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions.

Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, Trope CG, Ambudkar SV, Davidson B, Gottesman MM.

Mol Pharm. 2011 Dec 5;8(6):2080-8. doi: 10.1021/mp200240a. Epub 2011 Jul 15.

8.

Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status.

Bock AJ, Tuft Stavnes H, Kærn J, Berner A, Staff AC, Davidson B.

Tumour Biol. 2011 Jun;32(3):589-96. doi: 10.1007/s13277-011-0157-6. Epub 2011 Feb 26.

9.

PINCH-2 expression in cancers involving serosal effusions using quantitative PCR.

Yuan Y, Dong HP, Nymoen DA, Nesland JM, Wu C, Davidson B.

Cytopathology. 2011 Feb;22(1):22-9. doi: 10.1111/j.1365-2303.2010.00757.x.

10.

Lung cancer cytology: potential pitfalls and mimics - a review.

Idowu MO, Powers CN.

Int J Clin Exp Pathol. 2010 Mar 25;3(4):367-85. Review.

11.

Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions.

Davidson B, Stavnes HT, Holth A, Chen X, Yang Y, Shih IeM, Wang TL.

J Cell Mol Med. 2011 Mar;15(3):535-44. doi: 10.1111/j.1582-4934.2010.01023.x.

12.

Tenascin-X is a novel diagnostic marker of malignant mesothelioma.

Yuan Y, Nymoen DA, Stavnes HT, Rosnes AK, Bjørang O, Wu C, Nesland JM, Davidson B.

Am J Surg Pathol. 2009 Nov;33(11):1673-82. doi: 10.1097/PAS.0b013e3181b6bde3.

13.

Breast carcinoma cells in primary tumors and effusions have different gene array profiles.

Konstantinovsky S, Smith Y, Zilber S, Tuft Stavnes H, Becker AM, Nesland JM, Reich R, Davidson B.

J Oncol. 2010;2010:969084. doi: 10.1155/2010/969084. Epub 2009 Aug 11.

14.
15.

Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions.

Davidson B, Wang TL, Shih IeM, Berner A.

Hum Pathol. 2008 Apr;39(4):616-22. doi: 10.1016/j.humpath.2007.09.008. Epub 2008 Mar 4.

Supplemental Content

Support Center